Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma

Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor trametinib and did not respond to the BRAF inhibitor dabrafenib. We also...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Villanueva, Jessie, Infante, Jeffrey R., Krepler, Clemens, Reyes-Uribe, Patricia, Samanta, Minu, Chen, Hsin-Yi, Li, Bin, Swoboda, Rolf K., Wilson, Melissa, Vultur, Adina, Fukunaba-Kalabis, Mizuho, Wubbenhorst, Bradley, Chen, Thomas Y., Liu, Qin, Sproesser, Katrin, DeMarini, Douglas J., Gilmer, Tona M., Martin, Anne-Marie, Marmorstein, Ronen, Schultz, David C., Speicher, David W., Karakousis, Giorgos C., Xu, Wei, Amaravadi, Ravi K., Xu, Xiaowe, Schuchter, Lynn M., Herlyn, Meenhard, Nathanson, Katherine L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3956616/
https://ncbi.nlm.nih.gov/pubmed/24055054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2013.08.023
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge